Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.
follicular lymphoma
indolent B-cell non-Hodgkin lymphoma
low-dose radiotherapy
marginal zone lymphoma
primary cutaneous follicle center lymphoma
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
17
08
2019
revised:
09
11
2019
accepted:
06
12
2019
pubmed:
7
4
2020
medline:
14
5
2021
entrez:
7
4
2020
Statut:
ppublish
Résumé
In patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL), one course of low-dose radiotherapy (LD-RT) 2 × 2 Gy is emerging as new option of therapy in palliative setting. Efficacy of LD-RT when repeated remains to be determinate. This study aims to assess the efficacy of repeated LD-RT given in patients with indolent B-NHL. All consecutive adult patients who received two or more courses of LD-RT 2 × 2 Gy for indolent B-NHL at Gustave Roussy institution, during the period 1990-2015 were retrospectively investigated. Thirty-three patients received two or more courses of LD-RT for indolent B-NHL during the study period. The median age was 57 (range 37-80) years, histological types were distributed among follicular lymphoma (n = 24 pts; 73%), marginal-zone lymphoma (n = 6 pts; 18%), and primary cutaneous follicle center lymphoma (n = 3 pts; 9%). The median number of low-dose radiation therapy courses given per patients was 2 (range 2-6). The overall response rates following the first and the second course of LD-RT were 96% and 88%, respectively (P = .31). The 1- and 2-years local control rates following the first courses of LD-RT were 94% (CI 95: 86-100) and 94% (CI 95: 86-98); and were 91% (CI 95: 82-100) and 88% (CI 95: 77-100) following the second course of LD-RT (P = .39). The repeated courses of LD-RT offered similar efficacy compare with the first course in patients with indolent B-NHL. LD-RT repeated is a simple, easy to give, and non-toxic asset that could be investigated as treatment option in patients with indolent B-NHL.
Identifiants
pubmed: 32249547
doi: 10.1002/cam4.2796
pmc: PMC7286454
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3725-3732Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e385-9
pubmed: 22420970
BMC Med Res Methodol. 2012 Feb 01;12:9
pubmed: 22297116
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):154-8
pubmed: 18834672
J Clin Oncol. 1999 Apr;17(4):1244
pubmed: 10561185
Radiother Oncol. 1997 Jan;42(1):49-51
pubmed: 9132826
Cancer Med. 2020 Jun;9(11):3725-3732
pubmed: 32249547
J Clin Oncol. 2003 Jul 1;21(13):2474-80
pubmed: 12829665
Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):121-7
pubmed: 23414765
Ann Oncol. 2008 Dec;19(12):2043-7
pubmed: 18647962
Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):930-5
pubmed: 23726002
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):975-82
pubmed: 20970029
Eur J Cancer. 2005 Aug;41(12):1724-30
pubmed: 16039113
Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):148-55
pubmed: 11516864
Ann Oncol. 2017 Dec 1;28(12):3109
pubmed: 28327933
Lancet Oncol. 2014 Apr;15(4):457-63
pubmed: 24572077
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e781-6
pubmed: 21167657
Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1466-70
pubmed: 12459371
Cancer. 2010 Aug 15;116(16):3797-806
pubmed: 20564082
Blood. 2007 Aug 15;110(4):1116-22
pubmed: 17483295
Cancer. 2010 Aug 15;116(16):3843-51
pubmed: 20564102
Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):32-9
pubmed: 25863751
Strahlenther Onkol. 2018 May;194(5):454-461
pubmed: 29450588
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e1-6
pubmed: 21398049
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):522-529
pubmed: 30858143
Curr Treat Options Oncol. 2014 Jun;15(2):262-8
pubmed: 24700284
Hematol Oncol. 1994 Jan-Feb;12(1):1-8
pubmed: 8194839
Lancet Oncol. 2014 Apr;15(4):372-4
pubmed: 24572076
Immunol Rev. 2017 Nov;280(1):249-279
pubmed: 29027221